ArticleHerz2026
Prognosticating short-term outcomes in patients with STEMI-ACS and intra-procedural slow-flow/no-reflow phenomenon.
Article in Herz, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this study, we compared the incidence of short-term outcomes between two groups of patients based on the occurrence of intra-procedural slow-flow/no-reflow phenomenon (SF/NR) and identified predictors of short-term outcomes. This study enrolled a consecutive series of patients diagnosed with ST-elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI).
methodsThe patients were divided into two groups based on the presence or absence of SF/NR, and the incidence of short-term major adverse cardiovascular events (MACE) was compared between the two groups. Furthermore, the study aimed to identify predictors of short-term mortality in these patients. A total of 2582 patients were included, of whom 79.1% (n=2042) were male.
resultsThe average age of the patients was 55.7 ± 11.2 years. Intra-procedural SF/NR was observed in 21.7% (560) of the patients. During median short-term follow-up of 180 days (144-205), patients with SF/NR exhibited a higher incidence of all-cause mortality (23.6% vs. 12.3%; p < 0.001) and MACE (30.4% vs. 16.9%; p < 0.001), with a hazard ratio of 1.82 (1.46-2.27; p < 0.001) and 1.69 (1.39-2.05; p < 0.001), respectively. Among patients with SF/NR, the following were found to be independent predictors of short-term mortality (adjusted odds ratios): total ischemic time, 1.04 (1.00-1.07; p = 0.041); random blood sugar levels, 1.01 (1.00-1.01; p < 0.001); intubation status, 2.79 (1.26-6.18; p = 0.011); post-procedural sub-optimal flow, 1.76 (1.04-2.98; p = 0.034); and intra-procedural arrhythmias, 5.48 (2.03-14.79; p < 0.001).
conclusionThe presence of intra-procedural SF/NR has significant prognostic implications. Patients with intra-procedural SF/NR face a significantly higher risk of short-term adverse outcomes.
Indexed as
Identifiers
40810822What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.